Trial site
Shanxi Province Cancer Hospital
Taiyuan, Shanxi 30009, ChinaNot linked to an institution yet
- 12running trials
- 5closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 24 trials
- Status
- Active, not recruiting6 trials
- Completed5 trials
- Not yet recruiting5 trials
- Recruiting1 trial
- Lead sponsor
- Hoffmann-La Roche4 trials
- Amgen2 trials
- Shanxi Province Cancer Hospital2 trials
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.2 trials
- Allist Pharmaceuticals, Inc.1 trial
- and 6 more
Running trials
Not yet recruiting
Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy
NCT07627464· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Xuebing Han
Recruiting
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065· Phase 2· Guangzhou Lupeng Pharmaceutical Company LTD.· Source
Contact: Liping Su
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Recruiting
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
NCT06416410· Phase 3· Allist Pharmaceuticals, Inc.· Source
Contact: Shanghai Allist Pharmaceuticals Co., Ltd
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686· Phase 2· MediLink Therapeutics (Suzhou) Co., Ltd.· Source
Contact: Coordinator Clinical operation director
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
NCT05954910· Hoffmann-La Roche· Source
Active, not recruiting
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566· Phase 3· Amgen· Source
Recruiting
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
NCT05687357· Phase 2· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source
Contact: Yusheng Wang, MD
Recruiting
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
NCT05722275· Chinese Academy of Sciences· Source
Contact: Yanfen Cui, MD
Active, not recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error